期刊文献+

安罗替尼综合治疗软组织肉瘤的疗效分析 被引量:1

Analysis of the Efficacy of Anlotinib in the Treatment of Soft Tissue Sarcoma
下载PDF
导出
摘要 目的:探究无法完整手术切除的软组织肉瘤患者后期行安罗替尼联合传统化疗和单纯传统化疗的疗效对比。方法:1、收纳39例软组织肉瘤患者,均经手术切除后,组织病理学检测确诊,且手术无法完整切除肿瘤。23例采用安罗替尼联合化疗方案治疗,16例采用单纯化疗方案,最终对39例患者的疗效进行随访。结果:对比两组患者肿瘤复发时间的数据,并进行两组之间组间比较,安罗替尼组患者肿瘤复发时间和肺转移时间明显延长,差异有统计学意义(P 【0.05)。且在1年内软组织肉瘤患者复发率和肺转移率明显下降。结论:安罗替尼联合传统化疗治疗软组织肉瘤疗效好于单纯传统化疗治疗。 Objective: To compare the efficacy of anlotinib combined with conventional chemotherapy and con-ventional chemotherapy alone in patients with soft tissue sarcoma that could not be removed by complete surgery. Methods: Thirty-nine patients with soft tissue sarcoma were included, all of whom were confirmed by histopathological examination after surgical resection, and the tumor could not be completely removed by surgery. Twenty-three patients were treated with anlotinib combined with chemotherapy, 16 patients were treated with chemotherapy, and 39 patients were finally followed up for efficacy. Results: The data of tumor recurrence time in the two groups were compared between the two groups. The tumor recurrence time and lung metastasis time in the anlotinib group were significantly prolonged, with statistically significant differences (P
作者 葛淼 岳斌
出处 《临床医学进展》 2020年第3期320-326,共7页 Advances in Clinical Medicine
  • 相关文献

参考文献2

二级参考文献14

  • 1李兴训,张胜,尹东迎,冯业庆,巴拉提.库尔班,徐树森.调驱技术是低渗透油藏稳油控水的重要手段[J].新疆石油地质,2003,24(2):141-143. 被引量:23
  • 2Bannasch H,Eisenhardt SU,Grosu AL,et al.The diagnosis and treatment of soft tissue sarcomas of the limbs[J].Dtsch Arztebl Int,2011,108(3):32-38.
  • 3OByrne K,Steward WP.The role of chemotherapy in the treatment of adult soft tissue sarcomas[J].Oncology,1999,56 (1):13-23.
  • 4Hensley ML.Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas[J].Curr Opin Oncol,2010,22(4):356-361.
  • 5Hensley ML,Ishill N,Soslow R,et al.Adjuvant gemcitabine plus docetaxel for completely resected stages Ⅰ-Ⅳ high grade uterine leiomyosarcoma:results of a prospective study[J].Gynecol Oncol,2009,112(3):563-567.
  • 6Penel N,Bul BN,Bay JO,et al.Phase Ⅱ trial of weekly paclitaxel for unresectable angiosarcoma:the ANGIOTAX study[J].J Clin Oncol,2008,26 (32):5269-5274.
  • 7Demetri GD,Chawla SP,von Mehren M,et al.Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide:results of a randomized phase Ⅱ study of two different schedules[J].J Clin Oncol,2010,27(25):4188-4196.
  • 8Maki RG,D'Adamo DR,Keohan ML,etal.Phase.Ⅱ study ofsorafenib in patients with metastatic or recurrent sarcomas[J].J Clin Oncol,2009,27(19):3133-3140.
  • 9Grier HE,Krailo MD,Tarbell N J,et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarooma and primitive neuroectodermal tumor of bone[J].N Engl J Med,2003,348 (8):694-701.
  • 10Grist WM,Anderson JR,Meza JL,et al.Intergroup rhabdomyosarcoma study-Ⅳ:results for patients with nonmetastatic disease[J].J Clin Oncol,2001,19(12):3091-3102.

共引文献14

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部